ELTX
Elicio Therapeutics, Inc.
There isn't enough reported data to score ELTX yet.
ELTX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ELTX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
ELTX PE Valuation
ELTX has no meaningful PE right now: it lost money over the past year.
ELTX Forward outlook
There aren't enough analyst estimates for ELTX to show an outlook.
ELTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.83 | +$1.37 |
| Q2 2026 | -$2.13 | +$1.86 |
| Q1 2026 | -$2.36 | +$1.61 |
| Q4 2025 | -$2.58 | +$1.67 |
| Q3 2025 | -$3.20 | +$3.08 |
| Q2 2025 | -$3.99 | +$2.17 |
| Q1 2025 | -$3.97 | +$3.99 |
| Q4 2024 | -$4.25 | +$4.06 |
ELTX is still losing money, but far less than before: $1.83 per share over the past year, against $30.57 at its worst in late 2021.
ELTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $653K | +21% |
| Q1 2022 | $1.6M | +344% |
| Q4 2021 | $25.9M | +5552% |
| Q3 2021 | $1.5M | +77% |
| Q2 2021 | $540K | -26% |
| Q4 2020 | $459K | -34% |
ELTX's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2022 | -1384% | +1995 points |
| Q1 2022 | -879% | +4496 points |
| Q4 2021 | 56% | +3074 points |
| Q3 2021 | -1079% | +322 points |
| Q2 2021 | -3379% | -1010 points |
| Q1 2021 | -5374% | N/A |
| Q4 2020 | -3017% | -978 points |
| Q3 2020 | -1401% | N/A |
ELTX's operating margin was −1384% last quarter, up 1995 points from the same quarter a year ago.
ELTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.4M | +$722K |
| Q1 2026 | -$11.6M | -$1.5M |
| Q4 2025 | -$6.8M | +$2M |
| Q3 2025 | -$11.1M | -$3.8M |
| Q1 2025 | -$10.1M | +$2M |
| Q4 2024 | -$8.8M | +$1.1M |
| Q3 2024 | -$7.3M | -$2M |
| Q1 2024 | -$12.1M | -$4M |
ELTX has burned cash in almost every quarter: −$37M over the past year, against −$37M the year before.
ELTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +37% | +7M shares |
| 1 year | +58% | +9.6M shares |
| 3 years | +773% | +23.3M shares |
| 5 years | +1021% | +23.9M shares |
| Available history | +792% | +23.3M shares |
ELTX has 26M diluted shares, up 58% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q4 2020 | $36,000 |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ELTX Net Leverage
ELTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ELTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 13.2 | Oversold |
ELTX's weekly RSI is 33 (neutral) and its Stochastic is 13 (oversold).
ELTX PE vs Healthcare Sector
ELTX has no meaningful PE right now: it lost money over the past year.
ELTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.73 | 9.8% below |
| 20 week MA | $2.40 | 35% below |
| 50 week MA | $6.77 | 77% below |
| 100 week MA | $7.49 | 79% below |
ELTX is in a downtrend: it's below all four of its weekly moving averages, and 79% below its 100-week average.
ELTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $5.91 | $8.34 | +41% |
| 2024 | $8.34 | $5.15 | -38% |
| 2025 | $5.15 | $8.07 | +57% |
| 2026 YTD | $8.07 | $1.56 | -81% |
ELTX is down 81% so far in 2026, after finishing higher in two of the previous three years.